Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Net Margin: 2019-2025

Historic Net Margin for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -151.40%.

  • BridgeBio Pharma's Net Margin rose 577978.00% to -151.40% in Q3 2025 from the same period last year, while for Sep 2025 it was -225.31%, marking a year-over-year decrease of 2379.00%. This contributed to the annual value of -241.44% for FY2024, which is 667248.00% up from last year.
  • BridgeBio Pharma's Net Margin amounted to -151.40% in Q3 2025, which was up 7.97% from -164.52% recorded in Q2 2025.
  • BridgeBio Pharma's Net Margin's 5-year high stood at 17,732.17% during Q4 2021, with a 5-year trough of -40,632.84% in Q3 2022.
  • For the 3-year period, BridgeBio Pharma's Net Margin averaged around -4,141.99%, with its median value being -4,326.55% (2023).
  • Within the past 5 years, the most significant YoY rise in BridgeBio Pharma's Net Margin was 11,607,725bps (2021), while the steepest drop was 3,758,901bps (2021).
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Net Margin stood at 17,732.17% in 2021, then plummeted by 2,508,998bps to -7,357.81% in 2022, then plummeted by 227,818bps to -9,635.99% in 2023, then soared by 512,987bps to -4,506.12% in 2024, then skyrocketed by 577,978bps to -151.40% in 2025.
  • Its Net Margin was -151.40% in Q3 2025, compared to -164.52% in Q2 2025 and -143.55% in Q1 2025.